Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

3 trials in Phase 3/4

Results Transparency

57%

4 of 7 completed trials have results

Key Signals

4 with results

Enrollment Performance

Analytics

Phase 1

5(55.6%)

Phase 3

2(22.2%)

Phase 4

1(11.1%)

N/A

1(11.1%)

9Total

Phase 1(5)

Phase 3(2)

Phase 4(1)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT07075224Phase 1Not Yet Recruiting

Pharmacodynamics of a Fixed Dose Combination of 0.34% Tropicamide and 2.5% Phenylephrine Hydrochloride, Eye Drop, Solution

Role: lead

NCT05716763Phase 1Completed

Bioequivalence of IMP 08P1902F0 Relative to Contramal® (100 mg/mL Oral Solution)

Role: lead

NCT05406752Phase 1Completed

Pharmacokinetic Study of Paracetamol UNIFLASH (125 MG/1.25 ML)

Role: lead

NCT04622735Phase 3Completed

Nefopam/Paracetamol Fixed Dose Combination in Acute Pain After Impacted Third Molar Extraction

Role: lead

NCT06595121Phase 1Completed

Bioequivalence of IMP 08P1707F0 Relative to Pulmicort® (1.0 Mg/2 Ml Suspension)

Role: lead

NCT05129137Phase 1Completed

Pharmacokinetic Study of a Fixed Dose Combination Nefopam Hydrochloride (30 mg) / Paracetamol (500 mg)

Role: lead

NCT04640376Phase 3Completed

Paracetamol UNIFLASH for Buccal Use Phase III Trial in Acute Pain Due to a Tooth Extraction

Role: lead

NCT02626247Not ApplicableUnknown

Effect of Lipidic Nutrients on Memory and Well Being in Healthy Aging Adults

Role: collaborator

NCT02049112Phase 4Completed

A New Oral salIvary equivAlent Compared to Two moisturizinG Mouth sprAys in Patients With xeRostomiA: NIAGARA Study

Role: lead

All 9 trials loaded